P
Provention Bio
Clinical stage biopharmaceutical dedicated to sourcing, developing and commercializing novel therapeutics
About Provention Bio
Provention Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. The company operates in the healthcare sector, specifically targeting autoimmune and inflammatory diseases. Provention Bio serves patients who suffer from chronic conditions such as Type 1 Diabetes (T1D), Crohn's Disease, and Systemic Lupus Erythematosus. The company's business model revolves around the research, development, and commercialization of its therapeutic candidates. Revenue is generated primarily through partnerships, licensing agreements, and eventual product sales upon regulatory approval. Provention Bio aims to reduce the high morbidity, mortality, and escalating costs associated with these diseases by intervening before they begin, reappear, or progress. The company is dedicated to transforming treatment paradigms into interception and prevention strategies, thereby improving the quality of life for millions of patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2018
News
Open roles
Provention Bio in the Lebanon ecosystem
The Provention Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Johnson & Johnson Innovation
JDRF T1D Fund
MDB Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
Patents
20 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Provention Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


